Hepatitis News : Abbott’s Interferon-Free Hep C Regimen Boasts Over 90% Cure Rates
A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis News » November 2012


emailprint

November 13, 2012

Abbott’s Interferon-Free Hep C Regimen Boasts Over 90% Cure Rates

The future of hepatitis C treatment was looking bright at the annual meeting of the American Association of the Study of Liver Disease (AASLD) in Boston as pharmaceutical and biotech companies lifted the curtain on a panoply of results from their hep C pipeline research. As Reuters reports, among the most exciting results were the high cure rates from Abbott Laboratories’ three-drug regimen in development, which led to a sustained virological response in 93 percent of people with hepatitis C virus (HCV) who had failed a previous treatment and 97 percent of treatment-naive patients.

Abbott’s interferon-free regimen includes a protease inhibitor known as ABT-450, a polymerase inhibitor called ABT-333, and an NS5A inhibitor, ABT-267. The drugs were studied both with and without ribavirin among people with genotype 1 infections—the most difficult to treat strain, and the most common. The top cure rates were found in the ribavirin-inclusive regimen, although even without that antiviral drug the trio cured 87 percent of treatment-naive patients. All cures were achieved in only 12 weeks, and just 4 out of the 448 participants left the study because of adverse events. This suggests these drugs are highly tolerable—which is especially notable considering the flu-like symptoms common in the interferon-based regimens that are the standard of treatment today.

To read the Reuters story, click here.

Search: Hepatitis C, HCV, virus, Abbott, regimen, 90 percent, cure, SVR, sustained virologic response, American Association of the Study of Liver Disease, Boston, hep C, ABT-33, ABT-450, polymerase inhibitor, ribavirin, Interferon-free, NS5A inhibitor, genotype 1, protease inhibitor


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Are you planning to do anything for World Hepatitis Day on July 28?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.